MedTrace Logo

Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation

NCT02535286 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2022-10-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of targeted immunotherapy in combination with ublituximab and umbralisib, in patients with advanced CLL or Richter's Transformation.

Conditions

Interventions

DRUG

Umbralisib

A once daily oral agent

BIOLOGICAL

ublituximab

IV anti-CD20 monoclonal antibody

BIOLOGICAL

TG-1501

IV immunotherapy for cancer

Sponsors & Collaborators

Principal Investigators

  • Anthony R. Mato, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-18
Primary Completion
2021-11-04
Completion
2021-11-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02535286 on ClinicalTrials.gov